UNSPSC 51412005: Enoximone

This classification denotes a phosphodiesterase inhibitor with the molecular formula C12H12N2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C7Z4ITI7L7, chemically known as 1,3-dihydro-4-methyl-5-(4-methylthiobenzoyl)-2h-imidazol-2-one but generally known as enoximone, which bears US NIH Compound Identifier 53708. European Medicines Agency schedules Enoximone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06542MIG.

UNSPSC 51412005 Enoximone, a Commodity code, covers the procurement of specific pharmaceutical products for use by state and local health and emergency-response agencies. State and local governments buy under this code primarily through emergency medical services departments, health agencies, and hospital systems to stock advanced life support medications and specialty pharmaceuticals for acute-care protocols. Issuing bodies include city fire-rescue departments, state health and human services commissions, and multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions. The work involves securing reliable supply chains for time-sensitive medications with strict expiration-date windows, managing regulatory compliance (FDA, OSHA, cGMP, DSCSA), and coordinating delivery and replacement logistics to maintain continuous inventory for critical-care use.

Recent opportunities span Florida, Minnesota, and Texas. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26-P-00188) in April 2026 for Advanced Life Support Medications to be used by Tampa Fire Rescue, soliciting 370 units of Labetalol HCI, 1,810 units of Epinephrine, 330 units of Adenosine, and 1,020 units of Diltiazem with delivery within ten calendar days and a nine-month minimum expiration window; bids were due April 8, 2026, with an estimated contract value of $40,000 and a 5 percent bid discount for Small Local Business Enterprise participation. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP for Generic Multi Source Pharmaceuticals and OTC Products with proposals due March 26, 2026, requiring vendors to supply through three authorized wholesalers and establishing contracts effective July 1, 2026 with a two-year initial term; evaluation was weighted 75 percent on price competitiveness with secondary criteria for pricing format, EDI capability, and administrative compliance. The Texas Health and Human Services Commission issued a Request for Information (HHS0017013) in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs, seeking vendor capabilities for negotiated net-pricing models outside traditional PBM and wholesaler arrangements.